vs

Side-by-side financial comparison of CHAIN BRIDGE BANCORP INC (CBNA) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $14.7M, roughly 1.3× CHAIN BRIDGE BANCORP INC). CHAIN BRIDGE BANCORP INC runs the higher net margin — 36.4% vs -177.4%, a 213.8% gap on every dollar of revenue. CHAIN BRIDGE BANCORP INC produced more free cash flow last quarter ($11.5M vs $-23.1M).

Suburban Bancorp, Inc. was a publicly traded multibank holding company headquartered in suburban Chicago. It was founded by Gerald F. Fitzgerald, father of former U.S. Senator Peter Fitzgerald, and majority owned by the Fitzgerald family. Bank of Montreal acquired Suburban Bancorp, Inc. by merger in 1994. Harris Bankmont, Inc., an American subsidiary of Bank of Montreal, merged with Suburban Bankcorp to expand the Harris Bank presence in the Chicago area. The all-stock deal was valued at $246...

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CBNA vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.3× larger
LAB
$19.6M
$14.7M
CBNA
Higher net margin
CBNA
CBNA
213.8% more per $
CBNA
36.4%
-177.4%
LAB
More free cash flow
CBNA
CBNA
$34.6M more FCF
CBNA
$11.5M
$-23.1M
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CBNA
CBNA
LAB
LAB
Revenue
$14.7M
$19.6M
Net Profit
$5.3M
$-34.7M
Gross Margin
48.5%
Operating Margin
45.6%
-168.5%
Net Margin
36.4%
-177.4%
Revenue YoY
-11.5%
Net Profit YoY
-28.8%
EPS (diluted)
$0.81
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBNA
CBNA
LAB
LAB
Q4 25
$14.7M
Q3 25
$13.1M
$19.6M
Q2 25
$12.6M
$21.8M
Q1 25
$14.5M
$40.8M
Q3 24
$16.7M
$22.1M
Q2 24
$22.5M
Q1 24
$45.5M
Q4 23
$28.2M
Net Profit
CBNA
CBNA
LAB
LAB
Q4 25
$5.3M
Q3 25
$4.7M
$-34.7M
Q2 25
$4.6M
$-33.5M
Q1 25
$5.6M
$-26.0M
Q3 24
$7.5M
$-26.9M
Q2 24
$-45.7M
Q1 24
$-32.2M
Q4 23
$-19.8M
Gross Margin
CBNA
CBNA
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Q4 23
47.6%
Operating Margin
CBNA
CBNA
LAB
LAB
Q4 25
45.6%
Q3 25
44.9%
-168.5%
Q2 25
45.8%
-118.1%
Q1 25
48.4%
-80.8%
Q3 24
56.3%
-120.9%
Q2 24
-134.5%
Q1 24
-132.2%
Q4 23
-75.9%
Net Margin
CBNA
CBNA
LAB
LAB
Q4 25
36.4%
Q3 25
35.8%
-177.4%
Q2 25
36.3%
-153.7%
Q1 25
38.6%
-63.8%
Q3 24
44.8%
-122.0%
Q2 24
-203.3%
Q1 24
-70.6%
Q4 23
-70.2%
EPS (diluted)
CBNA
CBNA
LAB
LAB
Q4 25
$0.81
Q3 25
$0.72
$-0.09
Q2 25
$0.70
$-0.09
Q1 25
$0.85
$-0.07
Q3 24
$1.64
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27
Q4 23
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBNA
CBNA
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$586.6M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$169.2M
$399.7M
Total Assets
$1.8B
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBNA
CBNA
LAB
LAB
Q4 25
$586.6M
Q3 25
$395.7M
$129.4M
Q2 25
$377.3M
$158.6M
Q1 25
$629.2M
$150.9M
Q3 24
$639.8M
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Total Debt
CBNA
CBNA
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Stockholders' Equity
CBNA
CBNA
LAB
LAB
Q4 25
$169.2M
Q3 25
$163.1M
$399.7M
Q2 25
$156.9M
$424.5M
Q1 25
$151.5M
$454.6M
Q3 24
$104.8M
$489.3M
Q2 24
$510.3M
Q1 24
$577.3M
Q4 23
$-148.1M
Total Assets
CBNA
CBNA
LAB
LAB
Q4 25
$1.8B
Q3 25
$1.5B
$539.6M
Q2 25
$1.4B
$557.0M
Q1 25
$1.7B
$579.6M
Q3 24
$1.6B
$681.5M
Q2 24
$708.7M
Q1 24
$777.7M
Q4 23
$323.1M
Debt / Equity
CBNA
CBNA
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBNA
CBNA
LAB
LAB
Operating Cash FlowLast quarter
$15.6M
$-22.2M
Free Cash FlowOCF − Capex
$11.5M
$-23.1M
FCF MarginFCF / Revenue
78.1%
-118.1%
Capex IntensityCapex / Revenue
28.0%
4.5%
Cash ConversionOCF / Net Profit
2.92×
TTM Free Cash FlowTrailing 4 quarters
$17.9M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBNA
CBNA
LAB
LAB
Q4 25
$15.6M
Q3 25
$2.8M
$-22.2M
Q2 25
$3.4M
$-20.7M
Q1 25
$3.1M
$-30.3M
Q3 24
$-27.9M
Q2 24
$-39.0M
Q1 24
$-62.5M
Q4 23
$-14.1M
Free Cash Flow
CBNA
CBNA
LAB
LAB
Q4 25
$11.5M
Q3 25
$2.5M
$-23.1M
Q2 25
$2.5M
$-22.6M
Q1 25
$1.4M
$-35.3M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
FCF Margin
CBNA
CBNA
LAB
LAB
Q4 25
78.1%
Q3 25
18.7%
-118.1%
Q2 25
20.0%
-103.6%
Q1 25
9.8%
-86.6%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Capex Intensity
CBNA
CBNA
LAB
LAB
Q4 25
28.0%
Q3 25
2.5%
4.5%
Q2 25
6.5%
8.7%
Q1 25
11.6%
12.4%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Q4 23
0.3%
Cash Conversion
CBNA
CBNA
LAB
LAB
Q4 25
2.92×
Q3 25
0.59×
Q2 25
0.73×
Q1 25
0.55×
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBNA
CBNA

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons